Stichting European Myeloma Network

This phase 3 trial tests whether adding daratumumab to a standard three-drug regimen (VRd) improves outcomes for people with newly diagnosed multiple myeloma who can undergo high-dose therapy. About 709 participants will receive either the four-drug combo or the standard three dr…

This study compares two treatments for people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. One group gets standard chemotherapy plus a stem cell transplant, while the other gets the same chemotherapy followed by a new CAR-T cell therapy (cilt…

This study tests a combination of four drugs (daratumumab, bortezomib, cyclophosphamide, and dexamethasone) in 41 people with multiple myeloma that has spread outside the bones, known as extramedullary disease. The goal is to see how well the treatment works and how safe it is. P…